Early stage cancer biotech Precision BioSciences files for a $100 million IPO - (NASDAQ via NewsPoints Desk)

  • Precision BioSciences filed with the US Securities and Exchange Commission to raise up to $100 million in an initial public offering, as reported in NASDAQ.

  • The company, which was founded in 2006 and is developing gene-edited CAR T cell therapies for treating cancer, plans to list on the Nasdaq under the symbol DTIL.

  • No pricing terms were disclosed.

To read more NewsPoints articles, click here.